| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3334893 | Transfusion and Apheresis Science | 2015 | 6 Pages |
Abstract
Several plasma pathogen reduction technologies (PRT) are currently available. We evaluated three plasma PRT processes: Cerus Amotosalen (AM), Terumo BCT riboflavin (RB) and Macopharma methylene blue (MB). RB treatment resulted in the shortest overall processing time and in the smallest volume loss (1%) and MB treatment in the largest volume loss (8%). MB treatment retained the highest concentrations of factors II, VII, X, IX, Protein C, and Antithrombin and the AM products of factor V and XI. Each PRT process evaluated offered distinct advantages such as procedural simplicity and volume retention (RB) and overall plasma protein retention (MB).
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Luis Larrea, María-Isabel Ortiz-de-Salazar, Patricia Martínez, Roberto Roig,